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 Abstract 
Background: Clinicians have reported observations of the immediate cessation of non-
epileptic attacks after the diagnosis of NEAD is presented. 
Objective: The purpose of this systematic review was to examine the impact of receiving 
a diagnosis of NEAD. 
 
Search strategy: A literature search across the databases Medline, PsycINFO, EMBASE, 
and CINAHL, and additional hand searching, identified 6 original studies meeting criteria 
for the review. 
 
Selection Criteria: Included studies were original peer-reviewed articles investigating the 
impact of receiving a diagnosis of NEAD on adult populations with at least one outcome 
measured pre and post-diagnosis. 
 
Analysis: The studies were assessed for methodological quality, including biases. This 
assessment was developed to include criteria specific to research regarding NEAD and 
diagnosis. 
 
Results: Six identified studies, with a total of 153 NEAD participants, examined the 
impact of receiving a diagnosis on seizure frequency. Two of the six also examined the 
impact on health-related quality of life. The findings were inconsistent, with 
approximately half the participants experiencing seizure reduction or cessation post-
diagnosis. Diagnosis appeared to have no significant impact on health-related quality of 
life. The overall evidence lacked quality, particularly in study design and statistical 
rigour. 
 
Conclusions: Mixed results and a lack of high quality evidence was found. Concerns are 
considered regarding the appropriateness of seizure frequency as the primary outcome 
measure and the use of epilepsy control groups. Indications for future research include: 
measuring more meaningful outcomes, using larger samples and power calculations, and 
ensuring consistent and standard methods for communicating the diagnosis and 
recording outcomes.  
 
Keywords: Diagnosis, Non-Epileptic Attack Disorder, Prognosis, Psychogenic Non-
Epileptic Seizures, Systematic Review. 
 
 
 
 
  
 1. Introduction 
Non-epileptic attack disorder (NEAD) is the diagnostic term for people who experience 
non-epileptic attacks [1], also commonly referred to as Psychogenic Non-Epileptic 
Seizures (PNES). Although many terms have been used historically [2], in this review 
the terms non-epileptic attacks and NEAD will be adopted. Non-epileptic attacks have 
been defined as: episodes of altered behaviour which resemble epileptic seizures but are 
absent of the characteristic clinical and electrographic features of epilepsy [3]. 
Whilst epilepsy is caused by excessive discharges in the brain, Non-epileptic attacks 
(when other physiological causes are ruled out) are considered to have psychological 
causes [4]. Although there is no universally accepted theory [5], attacks are widely 
thought to occur in response to overwhelming distress triggered by difficult situations, 
thoughts, and emotions [6]. With NEAD patients mainly entering neurology services, the 
involvement of psychology has been delayed. With growing clinical and academic interest 
[7], it is anticipated that theoretical understanding and clinical implications will develop. 
It has been estimated that 20% - 30% of patients in neurology clinics for suspected 
epilepsy actually have NEAD [8,9]. Due to the topographical similarities, NEAD is often 
misdiagnosed as epilepsy, leading to inappropriate and potentially damaging treatment 
with antiepileptic drugs [10]. It takes an average of seven years before a revised NEAD 
diagnosis is reached [11]. To remedy this much of the research effort has focused on 
developing and validating a robust method for the differential diagnosis of NEAD [12]. 
The method of diagnosis considered the gold standard for sensitivity and specificity 
involves video-electroencephalogram (V-EEG) monitoring, whereby the 
electroencephalogram (EEG) records brainwave activity which is considered in 
conjunction with the clinical characteristics of the seizures observable on the video 
[13,14]. However, to complicate diagnosis and appropriate treatment, research using V-
EEG data suggests that NEAD is co-morbid in up to 10% of epilepsy patients [15,16]. 
Research into treatment for NEAD has only recently received the attention of systematic 
reviewers, concluding that high quality evidence for effective treatments is lacking 
[17,18].  
With comprehensive psychological theories and treatments yet to be established, 
clinicians often lack a good understanding of NEAD [19]. Consequent inadequate 
(potentially stigmatising) explanations to the patient can lead to confusion, anger, and 
disagreement with the diagnosis. Such reactions were associated with a poorer prognosis 
in terms of attack frequency and severity, and quality of life [19]. To provide clinicians 
with an adequate and non-stigmatising explanation for patients, several protocols have 
been developed [20-22].        
1.1. Rationale 
Within the literature, receiving a NEAD diagnosis is often referred to as the first stage of 
treatment [23-25]. This appears based on observations by clinicians that diagnosis can 
be interventive. Over the years clinicians have observed the communication of the 
diagnosis to result in the immediate cessation of attacks in some patients, negating the 
need for further treatment [e.g. 10,26]. To the author’s knowledge research has not 
attempted to explain this phenomenon, or the difference between those whose attacks 
cease and those whose attacks continue. As with many aspects of NEAD, theory 
development has fallen short, with categorisation taking its place [27-29]. 
Being aware of the reports that receiving a diagnosis can reduce/eliminate seizures, 
neurologists may be more considered with their communication of the diagnosis, seeing 
it as a possibly effective therapeutic task. On the other hand, it may perpetuate the 
historic perception of non-epileptic attacks being considered factitious/malingering [30]. 
 As the role of neurology post-diagnosis is yet to be widely agreed and implemented [31], 
these reports may serve to support services decisions to discharge patients from 
neurology upon diagnosis and offer no follow-up or formal pathway into psychology 
services. This lack of agreement on the role of neurology post-diagnosis is one factor 
contributing to the slow progress in establishing standard and effective management for 
patients [32].  
With the reports of diagnosis having a positive impact being well known and perhaps 
influential, it is important to consider the evidence as a whole before any conclusions 
should be made.   
1.2. Aims  
This review aims to synthesise the evidence regarding the impact of receiving a 
diagnosis of NEAD. The purpose of this review is to ascertain what the diagnosis impacts 
on, and whether the evidence is sufficient to draw any specific conclusions regarding the 
therapeutic effect of diagnosis.  
2. Method 
 
2.1.  Searching 
  
As previously noted the variation in terminology used in place of non-epileptic 
attacks and NEAD necessitated a comprehensive and inclusive search approach. 
Also, due to the paucity of literature in this area, historically used terms now 
deemed pejorative, such as hysterical seizures, and terms encompassing many 
phenotypes, such as somatoform disorders, were also included. For searching the 
databases, groups of terms relevant to two specific elements of the question were 
combined: non-epileptic attacks and NEAD; and diagnosis and outcome. 
 
Electronic searches were as follows: 
 
• CINAHL (1981 to July, week 3, 2014); 
• EMBASE (1980 to 2014 Week 29); 
• Medline (1947 to July week 3, 2014); and 
• PsycINFO (1910 to July week 3, 2014). 
 
The chosen databases include research literature from social science, nursing, 
and medical professions. Covering this range of disciplines was necessary due to 
the changing conceptualisation and continued variation in the management of 
NEAD patients. For full search strategies see supplementary information (online 
only). Additionally, the reference lists of included studies and several relevant 
reviews [5,38,39] were hand searched. 
 
2.2.  Selection 
 
In order to meet the aims of the review, a priori inclusion and exclusion criteria 
were developed. 
 
Literature was included if it: 
 
• Was original research. 
• Included adult participants. 
 • Explored the impact of receiving a diagnosis of NEAD (or one of its other 
known terms) with the requirement that seizures with psychogenic non-
epileptic origin rather than other medical causes were identified. 
• Included one or more outcome measure with data recorded/collected pre 
and post diagnosis. 
• Was written in English (due to the constraints of the study translation was 
not possible). 
 
Literature was excluded if it: 
 
• Did not specify that the diagnosis was the only ‘intervention’ before 
outcome data was collected, or if active treatment/intervention was 
reported following the delivery of the diagnosis and before follow-up data 
was collected. 
• Was not published in a peer-reviewed journal.  
• Was not an article length representation of the study (required to assess 
quality). 
 
A total of 8,011 articles were identified. The first author reviewed the titles and 
abstracts of articles for relevance. Articles were excluded at this stage for obvious 
violations of the inclusion criteria including: unrelated subject matter, papers 
other than original research and research with non-NEAD populations e.g. other 
somatoform disorder types. 196 papers remained after this process, 144 after 
duplicates were removed.  
 
Some articles remained due to the information in the abstract not allowing 
suitability to be determined, or because no abstract was immediately accessible. 
Four publications were found to be conference abstracts and were therefore 
excluded. The authors reviewed full texts for the remaining 140 articles to 
determine eligibility. Further papers were excluded for the obvious violations of 
inclusion criteria and other reasons including: active treatment before follow-up, 
presence of treatment not specified, retrospective data collection, and baseline 
data collected post-diagnosis. 
 
Hand searching of the six included studies [26,33-37] and relevant reviews 
[5,38,39] identified 12 additional potential studies, with three remaining after the 
initial abstract sift. Of these, one was a conference abstract and two were 
excluded when the full-text was reviewed. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 2.3 Summary of search and selection process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Articles found through 
electronic databases 
(n = 8011)  
CINAHL 
(n = 223) 
EMBASE 
(n = 3802) 
Medline 
(n = 1877) 
PsycINFO 
(n = 2109) 
Excluded by title and abstract 
review (n = 7815). 
Duplicate publications (n = 52) 
Conference abstracts (n = 4) 
Full text articles 
retrieved for review 
(n = 140) 
Excluded by full-text review 
(n = 134). 
Additional articles found 
through reference searching 
(n = 12) 
Excluded by abstract (n = 9) or 
full-text review (n = 2). 
Conference abstract (n = 1) 
Search 
Articles retained 
(n = 6) 
Articles included in 
systematic review 
(n = 6) 
 3. Results 
 
3.1. Data abstraction  
 
General characteristics were abstracted from the six studies, including: 
publication year, sample size, outcomes measured, and method of analysis. 
Additional characteristics relating to the sample and the control group (if 
applicable) were also recorded. Finally, the findings of each study were abstracted 
and summarised. All abstracted data are detailed in Table 1. 
 
3.2.  Outcomes measured 
 
3.2.1. Seizure frequency1 
 
Seizure frequency was measured in all of the studies but included a variety of 
methods of measuring/recording frequency. Three of the six studies recorded 
frequency of seizures in numerical form [26,35,36]. Three of the studies used 
a ranking system of seizure frequency (e.g. none, rare, or regular; monthly, 
weekly, or daily) [33,34,37]. The method of recording was less clear post-
diagnosis; with most studies reporting whether seizure frequency had ceased 
fully, increased, decreased, or remained the same. 
 
3.2.2. Health-related Quality of Life 
 
Health-related quality of life was measured in two of the six studies [35,37], 
both using Quality of Life In Epilepsy inventories, QOLIE-31 and QOLIE-10 
[40,41]. The QOLIE-31 is a measure of life satisfaction specific to patients 
with seizures although not specifically non-epileptic seizures. Scores range 
from 15-100 with a higher overall score representing better health-related 
quality of life. Within the measure are seven subscales: seizure worry, overall 
quality of life, energy/fatigue, emotional well-being, cognitive functioning, 
social life, and medication effects. Psychometric testing using a sample of 304 
adults with epilepsy found the lowest internal consistency on the social 
functioning subscale (0.77) and the highest on the cognitive functioning 
subscale (0.85) [40]. The QOLIE-10 was found to be highly correlated with 
the QOLIE-31 concluding that it could be used as a time saving alternative 
[41].   
 
 
 
 
 
 
 
                                                          
1 Seizure frequency will be the term used when reporting directly on reviewed studies, this is to ensure 
reporting accuracy and also due to the use of epilepsy control groups in some of the studies.  
 Table 1. Characteristics of included studies 
 
Primary author  Sample with NEAD  Control group  Methodology  Outcomes measured  Data collection points  Key findings   
Publication year  [N, event type, sex,  Design  
Reference  mean age (range)]  Analysis  
 
  N  Sex  Mean age (range)            
Duncan   
2011   
[33]  
 
54  44F, 10M  32.6 (NR)  None  Quantitative  
Prospective audit  
Inferential statistics*  
Seizure frequency  Baseline (pre), 3months  
(post), and 6 months  
(post)  
24/54 (44%) immediate cessation 
post diagnosis.  
Farias   
2003   
[26]  
 
22  14F, 8M  40.36 (NR)  10, ES, 4F 6M, 37.10  
(9.64)  
Quantitative  
Repeated measures  
Inferential statistics  
Seizure frequency  
  
24 hours either side of 
diagnosis  
21/22 (95%) reduced including 18/22 
(82%) total cessation, 3/22 (13%) 
50% reduction.   
Scheepers  
1994   
[34] 
  
27  20F, 7M  NR  None  Quantitative  
Retrospective audit  
Descriptive statistics  
Seizure frequency  Pre and post diagnosis  12/27 (44%) increase in frequency, 
15/27 (56%) reduction or same 
frequency.  
Thompson   
2013   
[35]   
19  11F, 8M  33 (18-66)  NR (sample of 19 
split), NEAD, NR  
Quantitative  
RC pilot  
Inferential statistics  
  
HRQoL, Seizure 
frequency and 
intensity  
Baseline (pre) and 6-8 
weeks (post)  
No significant differences in seizure 
frequency or HRQoL pre and post, or 
between intervention and control 
group.  
Wyllie   
1991   
[36]  
 
20  17F, 3M  34 (25-56)  Comparison group 
of 18 children  
Quantitative  
Repeated measures  
Inferential statistics*  
Seizure frequency  Baseline (pre) and 1 
year, 2 year and 3 year 
(post)   
4/20 (20%) immediate cessation post 
diagnosis.  
Zhang   
2009   
[37]  
 
11  8F, 3M  43 (33-53)  41, ES, 22F 19M, 39  
(28-50)  
Quantitative  
Repeated measures  
Inferential statistics  
HRQoL and Seizure 
frequency   
Baseline (pre) and 6-16 
months (post)  
Improvements in HRQoL but not  
statistically significant. Significant 
reductions in seizure frequency.  
Notes – F, female; M, male; NR, not reported; ES, epileptic seizures; RC, randomised control; * inferential statistics were used in the analysis but not for seizure 
frequency related to impact of diagnosis; HRQoL, health-related quality of life. 
  
3.3. Key findings  
 
3.3.1.  Impact of diagnosis on seizure frequency 
 
All of the reviewed studies provided data regarding the effect of the diagnosis on 
seizure frequency. Of the three studies where the primary aim was not to 
investigate the impact on diagnosis [33,35,36], two reported levels of seizure 
cessation post-diagnosis [33,36]. Mixed results were reported with seizure 
cessation in 24/54 participants (44%) in one study [33] and 4/20 (20%) in the 
other [36]. The third study [35] which primarily aimed to assess the impact of a 
brief educational intervention on engagement with further treatment, used a 
diagnosis only control group and reported no significant difference in seizure 
frequency post diagnosis.    
 
Of the two studies with epilepsy control groups, one reported a significant 
reduction in seizure frequency in both the NEAD and epilepsy groups [37]. The 
other [26] reported no change in seizure frequency in the epilepsy control group 
and a significant reduction in the NEAD group. Specifically, seizures reduced in 
21/22 participants (95%), with complete cessation in 18 (82%) and a 50% 
reduction in seizure frequency for the remaining 3 (13%). It was not reported 
whether the seizures increased or remained the same in the final participant.     
 
In the final study, which retrospectively reviewed the case notes of NEAD patients 
[34], it was reported that in 12/27 patients (44%) seizure frequency increased 
post diagnosis and in the other 15 patients (56%) seizure frequency stayed the 
same or decreased. However, this study included 15 patients with co-morbid 
epilepsy and NEAD and did not differentiate the changes in these patients and 
those with only NEAD. 
 
3.3.2. Impact of diagnosis on health-related quality of life 
 
Both of the studies which investigated the impact of diagnosis on health-related 
quality of life [35,37] found no significant difference (positively or negatively) 
pre- to post-diagnosis. 
  
 
3.4.  Assessment of Methodological Quality 
 
A meta-analysis was deemed inappropriate for combining and contrasting the 
results of the studies due to the heterogeneity of the measurement of seizure 
frequency [42]. Also, as will be later discussed, the quality of the studies raises a 
concern that an average result across the studies would not be meaningful. 
Instead, a narrative framework is used to describe the similarities and differences 
of findings.   
 
A domain-based quality evaluation tool was specifically developed for this review 
(see supplementary materials, online only). The developed tool incorporated 
elements of the Critical Appraisal Skills Programme (CASP) [43] and also 
considered previous (systematic) reviews relevant to NEAD populations [17,18]. 
 
The use of arbitrary cut-off scores in quality assessment tools have been criticised 
as important quality elements can be masked by the overall score and quality 
 label [44]. Also, single elements of quality can be more important than others in 
answering posed questions [45]. Therefore, this review adapted the tool 
developed by the Cochrane Collaboration [42], whereby shades represent levels 
of quality/bias. Although usually separated within Cochrane reviews, here, quality 
and bias are combined. No shading signifies low quality/high risk of bias, light 
shading represents, moderate quality/moderate risk of bias, and dark shading 
signifies high quality/low risk of bias.  
 
In order to assess the inter-rater reliability of the quality appraisal tool, 50% of 
the studies (selected at random) were independently rated by two authors (JB 
and NM). The mean kappa coefficient across items was .75, indicating 
'substantial' agreement overall [46]. 
 
The individual and synthesised assessment of quality can be seen in Table 3 and 
Table 4 respectively. Final ratings (presented in Table 3) represent scores agreed 
between the authors after independent appraisals and discussion of 
discrepancies. Table 4 displays the results of the synthesis of the quality and bias 
of the evidence as a whole. The overall quality and bias is considered by 
examining how many of the studies were judged as high quality for each criteria.  
 
 Table 2. Results of Quality Appraisal 
 
 
Study  1.  2.  3.  4.  5.  6.  7.  8.  9.  10.  11.  12.  13.  14.  15.  16.  17.  
Duncan 2011 [33]  +  +  ++  N/A  ++  ++  +++  +++  +++  ++  +++  +  +++  N/A  +  +  +  
Farias 2003 [26]  +  +++  ++  ++  ++  ++  +++  +++  +++  +  +++  +++  +++  N/A  +++  +  +++  
Scheepers 1994 [34]  +  +  ++  N/A  ++  +++  +++  +  N/A  N/A  ++  ++  +  N/A  +  +  +++  
Thompson 2013 [35]  +  +  ++  N/A  ++  +++  +++  +++  +++  +  +++  ++  ++  ++  +++  +  +++  
Wyllie 1991 [36]  +  +  +++  N/A  ++  +++  +++  +++  +  +  +++  ++  +++  N/A  +++  +  +++  
Zhang 2009 [37]  +  +++  +++  +++  ++  +++  +++  +++  ++  +++  +++  +++  +  ++  +++  +  +++  
  
Key    
+  Low quality/High risk of bias  
++  Moderate quality/Moderate risk of bias  
+++  High quality/Low risk of bias  
  
  
 
 
 
 
 
 
 
  Design  Participants   Diagnosis   Outcomes   Statistics   Reporting   
 Table 3. Synthesis of quality of evidence  
 
Criteria  Overall quality of evidence  
1. Power calculation       
2. Control group         
3. Demographics          
4. Matched controls               
5. Representative sample              
6. Inclusion and exclusion         
7. Take-up rate        
8. Confounding variables         
9. Attrition rate             
  10. Attrition comparison           
11. Diagnostic method         
12. Diagnosis delivery           
13. Outcome measures            
14. Standardised measures         
15. Statistical analysis         
16. Effect size       
17. Reporting bias         
  25%  50%  75%  100%  
  
 
 3.4.1. Results of Quality Assessment 
 
As can be seen in Table 2 the quality between and within the studies is mixed. 
Five of the studies reported all relevant demographics for the sample but in 
one study age was not reported [34]. However, in one of the five studies [35] 
the full sample was split into an experimental and control group but the 
numbers and demographics of each group were not reported.  
 
Power is the ability of a statistical test to detect a true effect of an 
intervention (in this case the delivery of the diagnosis) [47].  When adequate 
power is established the risk of a Type II error is low. Type II errors are false 
negatives where an effect exists but is not detected [47]. None of the studies 
reported power calculations. As sample sizes were small it is likely that they 
do not fully represent all of the population (people with NEAD), and this 
means the findings are unlikely to approximate population outcomes [47]. 
Additionally attrition rates may have impacted on the representativeness of 
the sample in some studies [26,36]. Take-up rates were reported, and found 
to be high, in four studies [34-37]; but were not reported in two studies 
[26,33].  
 
The statistically significant outcomes in the studies suggest that a difference 
exists but without conducting a meta-analysis it is unclear how robust such 
findings were to Type I errors. Type I errors are false positives, where an 
effect is detected but it can be attributed to chance [47]. Additionally, with no 
studies reporting effect size the magnitude of the differences was unclear 
[47]. This is particularly important when considering how effective 
interventions compare to each other [48]. Also, whilst four studies used 
inferential statistics to calculate the difference between pre and post 
measures [26,35-37], two only used descriptive statistics [33,34]. These were 
studies in which investigating the outcome of diagnosis was not the primary 
aim of the research.   
 
Four of the studies accounted for possible confounding variables in their 
design by using strict inclusion and exclusion criteria [26,33,35,36], one study 
identified participants with co-morbid ES and NEAD and accounted for this in 
the design and analysis [37]. One study [34], included patients with co-
morbid epilepsy and NEAD and did not differentiate when reporting changes in 
seizure frequency (which would have been possible due to the study having all 
individual data available retrospectively).   
 
With regard to NEAD research in particular, five of the six studies [26,33,35-
37] used the gold standard method for diagnosis, V-EEG monitoring [13,14]. 
The other study [34] used EEG data without a video overlay which is used to 
differentiate observable characteristics of seizures [14]. This was also the 
study which included co-morbid epilepsy and NEAD patients, which is perhaps 
an artefact of the method of diagnosis used being less specific. The delivery of 
the NEAD diagnosis was mixed in terms of a clear description but it was made 
clear in all but one study [33] that participants received the same diagnostic 
communication. Two of the studies [26,37] reported using a standard well-
regarded framework for the communication of the diagnosis [20]. The two 
studies which used control groups used matched controls of patients who 
were diagnosed with epilepsy (ES) [26,37]. 
 
 Seizure frequency was the main outcome and there are no standardised 
measures for recording this. The two studies which measured quality of life 
[35,37] used a tool standardised for an epilepsy population, the QOLIE [40, 
41]. As previously described, seizure frequency was operationalised differently 
in the studies. Three were considered to have operationalised the outcome to 
be measured objectively and clearly [26,33,36], including the two studies 
where only cessation or continuation of seizures were measured post 
diagnosis [33,36]. Two studies were considered to use less objective ways of 
measuring seizure frequency including ranking methods open to bias [34,35]. 
One study was considered to use a method open to bias and subjectivity 
which was different at pre and post diagnosis data collection points [37].  
 
Finally, five of the six studies reported in the results and discussion all 
data/measures described in the method [26,34-37]. One study collected data 
which was then not analysed/reported on in the results or discussion [33].  
 
3.4.2. Synthesis of quality  
 
As can be seen in Table 3, the overall evidence is not of a high standard with 
only four criteria being considered high quality/low bias in over 75% of the 
studies. The criteria reaching this standard were: take-up rates, reporting of 
data, diagnostic method, and controlling/adjusting for potential confounding 
variables. What can be judged and is of particular concern are the two criteria 
where low quality was identified in all studies. Power calculations and reported 
effect sizes are crucially important in drawing conclusions about presence and 
magnitude of impact [47]. Therefore the impact of receiving diagnosis may 
only be minimal and the accuracy of the results suggesting any impact is also 
questionable.  
 
4. Discussion  
 
This review explored the impact of receiving a diagnosis of NEAD. Six papers were 
included [26,33-37] to assess the evidence-base and the extent to which 
receiving a NEAD diagnosis impacts on non-epileptic attack frequency and to a 
lesser extent health-related quality of life.  
 
Quality assessment tools have typically been developed to assess the quality of 
randomised controlled trials and other specific research designs [49,50], and 
there is no consensus on which is the best tool [42]. For these reasons and the 
specific potential quality issues in this area of research, namely varying diagnostic 
methods, a domain-based quality evaluation tool was specifically developed for 
this review.  
 
Results found inconsistencies in the impact of receiving a diagnosis of NEAD. This 
may be influenced by the employment of heterogeneous methods of recording 
non-epileptic attacks. Also the quality of the research in terms of design and 
statistical rigour was highly questionable. This heterogeneity and lack of 
appropriate quality makes it difficult for any conclusions to be drawn regarding 
the impact of a NEAD diagnosis on attack frequency or health-related quality of 
life. 
 
Specifically it has been reported that receiving a diagnosis of NEAD can 
reduce/cease attacks [10,26]. No proposed explanation or theory for why this 
 may occur or why it happens in some people and not others was found in the 
current literature. Although difficult to calculate due to the heterogeneous 
methods of recording and reporting, approximately half of participants included in 
the studies in this review were found to experience a reduction or cessation in 
non-epileptic attacks post diagnosis. The wide range of reported levels of 
cessation (20-82%) raises questions about what may moderate response.   
The inconclusive, variable results and lack of quality found in this review indicate 
that further research is required. Health-related quality of life was measured in 
two of the six studies, finding no statistically significant changes in pre and post-
diagnosis measures [35,37].  
 
Without further investigation, it is difficult to conclude whether receiving a 
diagnosis of NEAD has any impact, positive or negative.  
 
4.1.  Limitations 
 
4.1.1. Limitations of this review 
 
The criteria for this review meant that studies must administer measures before and 
after the diagnosis of NEAD is delivered. This may have led to the exclusion of 
qualitative research regarding the personal experience and impact of receiving a 
diagnosis. It is advised that when further research is available which enables 
conclusions to be made about the objective impact of receiving a NEAD diagnosis, 
considering qualitative accounts of the impact may support the generation and 
testing of hypotheses regarding the mechanism of impact. 
 
Strict criteria were imposed on the literature in order to identify studies that would 
be able to answer the question: What is the impact of receiving a diagnosis of NEAD? 
Strict criteria applied to a well-researched area would enable the identification of high 
quality, specific studies which would increase the chance of the question being 
answered. However, the NEAD research pool remains small and at this time 
heterogeneous and poor quality studies mean that many questions are yet to be 
answered. Searching grey literature in any similar reviews in the future may provide 
more studies for consideration. 
 
Numerous papers were excluded as they reported collecting baseline data 
immediately after the diagnosis of NEAD was delivered (see Table 1.). It was felt that 
these studies would not answer the question regarding the impact of receiving a 
diagnosis. Also, numerous studies were excluded if there was no definitive statement 
of whether active treatment was implemented prior to follow-up data being collected 
(see Table 1.). This may be an error in reporting rather than conduct. 
 
With regard to quality assessment, in this review and generally, many items may 
reflect assessment of reporting rather than conduct [49]. Studies that did not report 
take-up rates may have concealed the rates to avoid selection bias criticism. 
Alternatively, take up rates may not be reported if standard service data was used 
and all participants were included as part of their service/treatment. 
 
The synthesis of the quality assessment was based on the system developed by the 
Cochrane Collaboration [42] intended to review large amounts of studies. Using this 
system in the current review with only six studies may be less useful.   
 
 
 4.1.2. Limitations of the included studies 
 
The scarcity of research is illustrated by the fact that investigating the impact of 
diagnosis was not the primary aim in half of the included studies [33,35,36]. Small 
sample sizes (11-54) were not surprising given the infancy of research into NEAD, it 
is suggest that the increasing interest in NEAD [7] will enable larger scale research to 
be undertaken in the future. 
 
Overall the methodological quality of the selected studies was poor. The lack of 
statistical rigour was apparent across all studies within this review, which limited the 
ability to draw conclusions. The different methods of recording attack frequency 
meant that it was difficult to synthesise the findings. The heterogeneity of the studies 
meant that a meta-analysis to calculate and synthesise effect sizes was not indicated 
[42]. 
 
Although there was consistency with all studies measuring seizure frequency as an 
outcome, it has been proposed that attack frequency, specifically attack cessation, 
should not be the primary outcome measured [51]. One study found no significant 
differences in the employment and benefit status of NEAD participants whose attacks 
ceased and whose attacks continued. In addition to this, in all participants who 
remained unemployed (attack free and continued attacks), there was no significant 
difference in psychopathology (anxiety and depression) [51]. Research has also 
found that quality of life improved in only 50% of participants whose attacks had 
ceased [52]. Furthermore, there was no significant correlation between quality of life 
and attack frequency overall. A study in this review supported the need for further 
consideration of meaningful outcomes [37]; statistically significant reductions in 
seizure frequency were found whereas the HRQoL did not show statistically 
significant improvement. There is also research which has found that cessation of 
non-epileptic attacks can result in their ‘replacement’ with other ‘conversion’ type 
symptoms [53]. This limitation can be further generalised to studies of treatment 
efficacy which also use seizure frequency as the primary outcome measure 
[17,18,54].  
 
As earlier described, one study did not differentiate between participants with NEAD 
and participants with co-morbid NEAD and epilepsy, in terms of the post-diagnosis 
outcome [34]. By not reporting on the outcomes for these groups separately no 
conclusions can be made about the impact of diagnosis on non-epileptic attack 
frequency in this study.  
 
4.2.  Future research 
 
Future research should endeavour to employ more statistically rigorous designs 
including larger sample sizes, and calculations of power and effect size. It is possible 
that research could utilise data already collected as in one of the studies in this 
review [34]. Twenty years on, data collected during inpatient assessment and 
diagnosis may be standardised and more comprehensive. This would enable direct 
comparisons of pre and post diagnosis measures without the complication of follow-
up after discharge increasing the risk of attrition.  
 
It is advised that future research standardises the collection of attack/seizure 
frequency data using V-EEG monitoring, as in one study included in this review [26]. 
If due to cost and prioritising equipment for clinical purposes this is not feasible, 
alternatives such as recording frequency in diaries could be considered. Research 
 should also prioritise measuring psychosocial, psychological, and medical outcomes 
to further explore their relationship to attack frequency and cessation [37,51,52]. 
Qualitative research is also indicated in order to explore what patients with NEAD 
consider a positive outcome.  
 
It would also be favourable for future research to standardise the communication of 
the diagnosis. Although two studies included in this review [26,37] adhered to a 
developed communication strategy [20], this has been succeeded by more recently 
developed protocols [21,22]. With confusion about NEAD associated with poorer 
prognoses [19], more up to date protocols with more educational information may 
improve outcomes. It may be useful to compare outcomes after using various 
communication strategies. A study in this review compared standard diagnostic 
communication with a brief educational intervention, but found no significant 
differences in HRQoL or seizure frequency between groups [35].  
 
As noted earlier, the reported levels of cessation in this study were wide ranging (20-
82%). If future studies with more rigorous designs continue to find such variability, it 
would be appropriate to explore what may moderate response. Patient, clinician, or 
process characteristics (including the communication strategy) may account for 
variability in the outcomes of diagnosis. Existing research has identified predictors of 
outcome, typically patient characteristics, but this has focused on responses to active 
treatment or longer-term follow up rather than diagnosis [10,19,24,36,55-57].  
 
Research, including one study in this review, found that epileptic seizures can also 
reduce post-diagnosis [37,58]. The topographical similarities led to NEAD being 
commonly misdiagnosed as epilepsy [10]. NEAD once being a diagnosis based on the 
exclusion of epilepsy [13,14] has left a legacy of epilepsy patients continuing to be 
utilised as a control group in NEAD research. With the theory that non-epileptic 
attacks are underpinned by psychological processes being widely accepted [4], why 
are patients with epilepsy, underpinned by neurological processes, considered a 
suitable control group? It may be more appropriate to compare NEAD with other 
psychological phenomena - further investigation of this is recommended.  
 
5. Conclusions 
 
Clinicians have reported their observations that receiving a diagnosis of NEAD has a 
positive impact, particularly by reducing/ceasing seizures. The results of this review 
have found that a limited evidence base of six studies including 153 participants was 
not consistent or of sufficient quality to draw definitive conclusions regarding this. 
More rigorous research is required to understand the impact receiving a NEAD 
diagnosis has on various outcome measures. 
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